Moreover, SRGN expression in GBM exhibits a strong positive correlation with the expression of inflammatory ligands such as IL-8, CCL-20, CCL-2, IL-6, IL-1β, CXCL-1 and TGFβ1, strong-to-moderate positive correlation with inflammatory receptors including TGFβRI and CXCR-2 and moderate-to-weak positive correlation with proteases and inhibitors such as PAI-1, uPA, MMP-14, MMP-9, MMP-2 and MMP-1 (Figure 1F and Table S3). This evidence concerns the gene CCL2 and glioblastoma.